MedTrace Logo

Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction

NCT00982033 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2019-02-27

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to determine whether treatment with aliskiren (300 mg) compared to placebo will improve treadmill exercise time in older (age ≥ 55 years) patients with heart failure and normal ejection fraction (HFNEF).

Conditions

Interventions

DRUG

aliskiren

aliskiren 300mg qd versus placebo for 24 weeks.

DRUG

placebo

placebo qd for 24 weeks

Sponsors & Collaborators

Principal Investigators

  • Dalane W Kitzman, MD · Wake Forest University Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2011-09-30
Completion
2011-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00982033 on ClinicalTrials.gov